Holdings
Amplify Weight Loss Drug & Treatment ETF
As of Jun 30, 2026, Amplify Weight Loss Drug & Treatment ETF reported 20 positions worth US$4.25M. Largest: Novo Nordisk A/s Class B, Eli Lilly And Company and Scholar Rock Holding Corporation. What it bought and sold, with each filing.
| Company | Shares | Value as reported | Change | As of |
|---|---|---|---|---|
| Novo Nordisk A/s Class B | 9,001 | US$426K | −4,128 | Jun 30, 2026 |
| Eli Lilly And Company | 337 | US$404K | −185 | Jun 30, 2026 |
| Scholar Rock Holding Corporation | 4,531 | US$249K | +2,526 | Jun 30, 2026 |
| Hims & Hers Health, Inc. | 7,013 | US$243K | new | Jun 30, 2026 |
| Viking Therapeutics, Inc. | 6,142 | US$240K | +3,324 | Jun 30, 2026 |
| Abbvie Inc. | 901 | US$227K | −6 | Jun 30, 2026 |
| Arrowhead Pharmaceuticals, Inc. | 2,722 | US$222K | −565 | Jun 30, 2026 |
| Innovent Biologics, Inc. | 21,500 | US$218K | +4,500 | Jun 30, 2026 |
| Amgen Inc. | 552 | US$200K | −188 | Jun 30, 2026 |
| Chugai Pharmaceutical Co., Ltd. | 4,300 | US$199K | −300 | Jun 30, 2026 |